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ttp://dx.doi.org/10.1016/j.ajpath.2015.11.005Remyelination is the regenerative response to demyelination. Although the oligodendrocyte pro-
genitor is established as the major source of remyelinating cells, there is no conclusive evidence on
whether mature, differentiated oligodendrocytes can also contribute to remyelination. Using two
different inducible myelin-CreER mouse strains in which mature oligodendrocytes were prelabeled by
the expression of membrane-bound Green ﬂuorescent protein, we found that after focal spinal cord
demyelination, the surrounding surviving labeled oligodendrocytes did not proliferate but remained
at a consistent density. Furthermore, existing (prelabeled) oligodendrocytes showed no evidence of
incorporation or migration into the lesioned area, or of process extension from the peripheral margins
into the lesion. Thus, mature oligodendrocytes do not normally contribute to remyelination and are
therefore not a promising target for regenerative therapy. (Am J Pathol 2016, 186: 511e516; http://
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Disclosures: None declared.The translational challenge of promoting remyelination
therapeutically in chronic demyelinating diseases such as
multiple sclerosis requires an understanding of the cells
that are involved in generating new oligodendrocytes after
demyelination. Although it is now ﬁrmly established that
oligodendrocyte progenitors (OPs), a population of
abundant and widely distributed multipotent adult central
nervous system progenitors, are the major source of new
remyelinating oligodendrocytes,1,2 uncertainty has sur-
rounded the contribution made by mature oligodendro-
cytes. It has been suggested that mature myelin-forming
oligodendrocytes may be able to undergo cell division,
implying that they have the potential to generate new cells
for remyelination.3e5 However, two lines of evidence have
strongly suggested that this was not the case.6 The ﬁrst was
the observation that oligodendrocytes that survive demy-
elination, albeit no longer supporting myelin sheaths, make
no contribution to subsequent remyelination.7 A second
study showed that culture-derived oligodendrocytes aretigative Pathology. Published by Elsevier Inc. Tunable to remyelinate demyelinated axons after trans-
plantation.8 However, the conclusions drawn from both
studies can be challenged. In the ﬁrst, to distinguish
oligodendrocyte-derived remyelination from OP-derived
remyelination, the lesioned tissue was exposed to very
high levels of X-irradiation to suppress OP proliferation,
and no remyelination was seen subsequently, suggesting
that only proliferating OPs and not postmitotic OLs are
capable of remyelinating. However, in the process, not
only OPs but also all other cells, including surviving oli-







Figure 1 A: Transgenic mouse strains: A reporter mouse strain, in which
membrane-bound Green ﬂuorescent protein (mGfp) and b-galactosidase (LacZ)
are under the control of the Tau promoter, was crossed to either of two
inducible Cre strains in which Cre recombinase expression was restricted to
mature oligodendrocytes using the Mbp or Opalin promoters. Excision of the
STOP sequence by tamoxifen-inducible Cre recombination results in expression
of mGfp and LacZ. B: Schematic diagram of the lysolecithin microinjection site
in the white matter of the spinal cord ventral funiculus. IRES, internal ribo-
some entry site; NLS, nuclear localisation sequence; pA, polyadenylation.
Crawford et alX-irradiation, perhaps impairing their normal function and
rendering them incapable of a potential regenerative
response of which they might have been capable under
physiological circumstances. In the second, the derivation
and maintenance of oligodendrocytes in culture before
their experimental introduction into areas of demyelination
might have compromised their ability to remyelinate.
To resolve this issue, we used two new mouse strains that
express tamoxifen-inducible form of Cre recombinase
(iCreER) exclusively in differentiated oligodendrocytes
(OLs), under myelin basic protein (Mbp) or Opalin (also
known as transmembrane protein 10) transcriptional con-
trol.9,10 These were used in combination with a t-mGfp-
LacZ reporter strain, to prelabel mature OLs with
membrane-bound Green ﬂuorescent protein (mGfp) and b-
galactosidase. This has enabled us to assess the contribution
of oligodendrocytes under normal physiological conditions
(exposed to neither X-irradiation nor to tissue culture) to
remyelination after toxin-induced demyelination. We found
no incidence of prelabeled OLs contributing to remyelina-
tion and therefore provide deﬁnitive evidence that mature
myelinating oligodendrocytes make no signiﬁcant contri-
bution to their regeneration.
Materials and Methods
Generation of Transgenic Animals
An Mbp-iCreERT2 transgenic mouse strain was made
using small plasmid transgenesis. A 5.89-Kbp upstream
region of Mbp (promoter fragment) was used for driving
iCreERT2 with parts of Plp exons 6 and 7 downstream,
followed by a poly(A) sequence. The Plp downstream
fragment was puriﬁed from plasmid Mbp,11 kindly gifted
by Brian Popko, University of Chicago (Chicago, IL). An
Mbp promoter fragment (9 Kbp) was gifted by Alan
Peterson (McGill University, Montreal, QC, Canada) and
reduced to 5.89 Kbp by digest with KpnI. This approxi-
mately 6-Kbp fragment lacks the Schwann cell enhancer
(M4) located at approximately 9 Kbp relative to the
transcriptional start site.12 The iCreERT2 cassette [gifted
by Marcus Fruttiger, University College London (Lon-
don, UK)] was synthesized according to the published
sequence. The ﬁnal Mbp-iCreERT2-Plp plasmid transgene
was assembled and puriﬁed from the plasmid backbone
before pronuclear injection. Two founders were obtained,
and as both had similar expression patterns and intensity,
one was selected for further characterization.
The Opalin-iCreERT2 mouse was generated via bacterial
artiﬁcial chromosome transgenesis using theOpalin genomic
bacterial artiﬁcial chromosome RP24-510M10. Insertion of
the iCreERT2-polyA-frt-Kanamycin-frt cassette was achieved
by homologous recombination (with no loss of the genomic
bacterial artiﬁcial chromosome) immediately after theOpalin
initiation codon ATG of the open reading frame of theOpalin
sequence. The frt-kanamycin-frt was removed using ﬂippase512recombinase. The bacterial artiﬁcial chromosome was line-
arized using Nocardia otitidis-caviarum I restriction enzyme
before gel puriﬁcation and pronuclear injection. Four foun-
ders were generated, three of which expressed the transgene.
The one with highest expression was chosen for further
experimentation. Both the Mbp-iCreERT2 and the Opalin-
iCreERT2 mice were generated on a C57BL/6 CBA mixed
background.
Cell-type speciﬁcity of the inducible CreER strains was
assessed by crossing them individually to Rosa-Yfp and
immunolabeling double-transgenic offspring (after tamoxifen
injection) for yellow ﬂuorescent protein and platelet-derived
growth factor receptor alpha (OP), sex-determining region Y
box 10 (OL lineage cells), or adenomatous polyposis coli
antibody hybridoma clone (differentiated OLs). Both CreER
strains were highly speciﬁc for sex-determining region Y
box 10epositive, CC1þ OLs (R.B. Tripathi, I. McKenzie,
and W.D. Richardson, manuscript in preparation). Here, to




Mice (both males and females) carrying the Opalin-
iCreERT2 and Mbp-iCreERT2 transgenes were conﬁrmed
by PCR using the following primers against the iCre
region (forward/reverse): 50-GAGGGACTACCTCCTG-
TACC-30/50-TGCCCAGAGTCATCCTTGGC-30. t-mGfp-




Tamoxifen (10 mg/mL) was prepared in ethanol/sunﬂower
oil (1:9) by sonication for 35 to 45 minutes and administeredajp.amjpathol.org - The American Journal of Pathology
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Figure 2 A: Five days postlesion (dpl) in Mbp-iCreERT2:Tau-mGfp-LacZ mouse: dashed line indicates presumed lesion edge (based on increased cell
density), with lesioned tissue on the right. B: Ki-67þ cells in the lesion and in perilesion white matter (WM) at 5 dpl: no surrounding Green ﬂuorescent protein
(Gfp)-positive oligodendrocytes (OLs) (indicated by arrowheads) costain for Ki-67. C: Number of Gfpþ cells in contralateral and perilesion WM at 5 and 21 dpl:
no signiﬁcant difference was detected. DeF: At 21 dpl, membranous Gfpþ processes do not extend into adjacent areas of remyelination. Adenomatous
polyposis coli antibody hybridoma clone CC1epositive OLs: with images from two separate animals (D and E), and myelin basic protein (Mbp)-positive myelin
sheaths (F) conﬁrm remyelination of lesioned area. Data are expressed as means  SEM. PZ 0.69 at 5 dpl, PZ 0.13 at 21 dpl (Student’s t-test). Scale barsZ
20 mm. Original magniﬁcation: 20 (A); 40 (B, D, and E); 63 (F). Hst, hoechst.
Mature Oligodendrocytes Do Not Remyelinateat a dose of 55 mg/kg via i.p. injection on 4 successive days.
Mice used in this study were aged P64 to P99 (mean, P77).
The last tamoxifen injection was given 14 days before the
demyelinating lesions were generated, to prevent any further
ongoing recombination during and after the lesioning
procedure.Focal Spinal Cord Demyelination
Primary demyelination was induced in the caudal thoracic
ventral funiculus of the spinal cord by injection of 1%
lysolecithin as previously described1 (Figure 1B).Tissue Processing
Mice were ﬁxed by intracardiac perfusion at 5 (n Z 3)
or 21 (n Z 6) days postlesion induction (dpl) using
4% (w/v) paraformaldehyde in 0.1 mol/L phosphate-
buffered saline. Spinal cords were removed and post-
ﬁxed in 4% paraformaldehyde for 2 hours at room
temperature, then cryoprotected with 20% (w/v) sucrose
for 24 to 48 hours, and ﬁnally embedded and frozen in
OCT medium and stored at 80C. Spinal cords were
sectioned at 12-mm nominal thickness and collected onto
Polysine-coated glass slides (Thermo Fisher Scientiﬁc
Inc., Rochester, NY).The American Journal of Pathology - ajp.amjpathol.orgImmunocytochemistry and Microscopy
Spinal cord sections were pretreated with blocking solution
[8% (v/v) normal goat serum, 0.1% (v/v) Triton X-100 in
phosphate-buffered saline], incubated with primary antibodies
overnight at 4C and then secondary antibodies for 2 hours at
20C to 25C. Primary antisera were chicken anti-Gfp (1:1000
dilution; Aves Labs, Inc., Tigard, OR), rabbit anti-LacZ
(antieb-galactosidase) (1:2000; MP Biomedicals, Solon,
OH), mouse monoclonal anti-CC1 (antieadenomatous polyp-
osis coli) (Calbiochem, 1:100; EMDMillipore Corp., Billerica,
MA), rat anti-Mbp (1:400; AbD Serotec, Raleigh, NC), rabbit
antieKi-67 (1:1000; Abcam plc, Cambridge, UK), and mouse
monoclonal antieproliferating cell nuclear antigen (1:300;
Santa Cruz Biotechnology, Inc., Dallas, TX). Secondary
antibodies were goat anti-chicken Alexa Fluor 488, goat
anti-rabbit Alexa Fluor 647 (1:500), goat anti-mouse IgG2b
Alexa Fluor 568. Alexa Fluor antibodies (InvitroGen, Carlsbad,
CA) were used at 1:1000 dilution unless otherwise stated. All
antibodies were diluted in the blocking solution. All Gfp
expression was detected by immunolabeling. Cell nuclei were
visualized by post-staining with Hoechst 33258 (1:1000;
Sigma-Aldrich Corp., St. Louis, MO). Sections were mounted
under coverslips and examined in a Leica TCS SPE confocal
microscope (Leica Microsystems, Buffalo Grove, IL). For cell
counts, at least three sections per animal were examined. Data
are quoted as means  SEM (nZ 3 to 6).513
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Figure 3 A: Five days postlesion (dpl) in Opalin-iCreERT2:Tau-mGfp-LacZ
mouse: Ki-67eGreen ﬂuorescent protein (Gfp)-positive oligodendrocyte
(OL) from the presumed lesion edge surrounded by Ki-67þ cells. B: Number
of membranous Gfpþcells in contralateral and perilesion white matter
(WM) at 5 and 21 dpl: no signiﬁcant difference is detected. C: Gfpþ OLs
surrounding the lesion make no contribution to remyelination at 21 dpl
(lesion right of dashed line). Fragments of Gfpþ staining are present
within the lesion, but the morphology is not consistent with a myelinating
cell and are presumed to be labeled myelin debris generated during
demyelination that has not been cleared from the lesion. D: Gfpþ OL
adjacent to remyelinated lesion: remyeination shown by myelin basic
protein (Mbp)-positive myelin sheaths. Data are expressed as means 
SEM. PZ 0.56 at 5 dpl, PZ 0.75 at 21 dpl (t-test). Scale barsZ 20 mm.
Original magniﬁcation: 63 (A and C); 40 (B). Hst, hoechst.
Crawford et alStatistics
SPSS software version 22 (SPSS Inc., Chicago, IL) was used
for conﬁrming normal distribution of the data. The Student’s
t-test was used for determining signiﬁcant differences among
groups, and P < 0.05 was considered signiﬁcant.Results
Mbpþ Oligodendrocytes Show No Signiﬁcant
Contribution to Remyelination
To determine whether mature oligodendrocytes can contribute
to the regeneration of an adjacent area of demyelination, we
crossed the Mbp-iCreERT2 strain to a reporter mouse strain in
whichLacZ andmGfp are under the control of the tau-promoter.
After tamoxifen administration, mature oligodendrocytes
expressing Mbp undergo recombination and activation of
expression of LacZ and mGfp. Recombination efﬁciency was
found to be very high in this strain, with 74.4%  12% of
mature, CC1þ oligodendrocytes successfully labeled.
A focal area of demyelination was induced by the injec-
tion of lysolecithin, leading to the local depletion of mGfpþ514oligodendrocytes by 5 dpl (Figure 2A). By 21 dpl, the
lesioned area had been repopulated with CC1þ cells
(Figure 2, D and E) and Mbpþ myelin sheaths, conﬁrming
remyelination. However, no mGfpþ, LacZþ oligodendro-
cytes were found within the lesioned area at 5 or 21 dpl
(Figure 2, A, B, and DeF). This ﬁnding suggests that
mature oligodendrocytes are not recruited into the area un-
dergoing remyelination. Furthermore, there was no detect-
able process extension from surviving mGfp-labeled
oligodendrocytes around the lesion periphery into the region
undergoing remyelination (Figure 2F). Hence, surrounding
oligodendrocytes show no detectable extension of new
myelin sheaths to locally demyelinated axons.
Ki-67 was used as a marker of cells actively replicating at
the time of sacriﬁce. Abundant Ki-67þ cells were detected
within the demyelinated lesion at 5 dpl (Figure 2B). Gfp-
labeled oligodendrocytes surrounding the lesion periphery
did not colabel with Ki-67, suggesting that oligodendrocytes
do not proliferate in response to a local area of acute
demyelination. In support of this conclusion, we did not ﬁnd
any cells that coexpressed LacZ and proliferating cell nu-
clear antigen, expressed during the DNA synthesis stage of
the cell cycle (data not shown). The number of Gfpþ, LacZþ
oligodendrocytes in the normal ventral funiculus was
compared to that in the region immediately surrounding the
lesion at 5 and 21 dpl; no signiﬁcant differences were
detected (Figure 2C). Therefore, preexisting oligodendro-
cytes do not divide in response to focal acute demyelination.
We recently discovered that the Mbp-iCreERT2 reporter
mouse strain can undergo spontaneous recombination,
thereby labeling cells independently of tamoxifen adminis-
tration, presumably because of the high iCreERT2 expres-
sion in this strain. However, this did not appear to be an
issue in this study as no labeled cells were identiﬁed within
the demyelinated area; also we did not detect an increase in
labeled cells within the 21-day experiment time frame.
However, the high recombination efﬁciency prevented
single-cell analysis. To ensure that spontaneous recombi-
nation was not inﬂuencing our ﬁndings and to enable single-
cell visualization, the experiment was repeated using an
Opalin-iCreERT2 strain.
Opalinþ Oligodendrocytes Show No Signiﬁcant
Contribution to Remyelination
The tau-mGfp reporter mice were crossed to the Opalin-
iCreERT2 mice; oligodendrocytes expressing Opalin at the
time of tamoxifen administration would be expected to label
with mGfp. The extent of recombination was much lower
than with the Mbp-Cre strain, resulting in 6.5%  0.8% of
CC1þ oligodendrocytes expressing mGfp. This relative
scarcity enables the visualization of individual cells and
their extensive myelinating processes (Figure 3A).
Analysis of the lesioned region showed an absence of
mGfpþ oligodendrocytes at both 5 and 21 dpl. Labeled
oligodendrocytes surrounding the lesion periphery showedajp.amjpathol.org - The American Journal of Pathology
Mature Oligodendrocytes Do Not Remyelinateno detectable process extension into the lesioned region
(Figure 3, B and C). Staining for the Ki-67 antigen revealed
abundant proliferating, Ki-67þ cells within the demyeli-
nated area at 5 dpl, but there was no costaining of
surrounding, mGfpþ oligodendrocytes. Similarly, we did
not ﬁnd any cells that coexpressed LacZ and proliferating
cell nuclear antigen (data not shown). Also, the number of
Gfp-labeled cells remained constant in the normal ventral
funiculus at 5 and 21 dpl (Figure 3D). Therefore, the use of
two transgenic mouse strains in which mature oligoden-
drocytes can be effectively visualized failed to detect
oligodendrocyte contribution to the remyelination of a
toxin-induced, acutely demyelinated lesion.Discussion
Areas of remyelination contain a greater number of oligo-
dendrocytes compared to normal white matter, indicating that
remyelination requires the generation of new oligodendro-
cytes.6,14 This is dependent on cellular proliferation; exposing
a demyelinated region of spinal cord to X-irradiation at a dose
sufﬁcient to cause the death of dividing cells prevents
remyelination.15 The major proliferating cell population in the
adult central nervous system is the OP,16 whose activation and
recruitment in response to demyelination have been exten-
sively documented.17,18 However, whether mature oligoden-
drocytes can also contribute to the remyelination process has
remained unclear.
Initial studies suggested that oligodendrocytes could
undergo a proliferative response after a demyelinating
insult, based on their incorporation of tritiated thymi-
dine.3,19 Subsequent studies, utilizing various experimental
strategies such as irradiation, proliferation assays,7 and cell
transplantation,8 have suggested that oligodendrocytes do
not proliferate in response to demyelination, nor do they
contribute to remyelination. However, each of these stra-
tegies has the potential to interfere with the normal cellular
physiology of the oligodendrocyte.
In this study, transgenic mouse strains were used in which
mature, differentiated oligodendrocytes are labeled by a
membrane-bound Gfp after the administration of tamoxifen,
thus enabling their assessment in a normal in vivo environ-
ment. This technique does not compromise the physiology of
the oligodendrocyte and enables the remyelination process to
proceed unhindered by any potential adverse effects of irra-
diation, immunosuppression, or transplantation.
A model of toxin-induced demyelination was used in
which a focal area of acute demyelination was generated by
the injection of lysolecithin. This lesioned area was depleted
of mature oligodendrocytes by 5 dpl and became repopu-
lated with CC1þ oligodendrocytes and Mbpþ myelin
sheaths after 21 days. This repopulation was devoid of Gfp-
labeled cells, suggesting that there was no signiﬁcant
contribution of the labeled, mature oligodendrocytes to this
area of remyelination. There was no detectable proliferativeThe American Journal of Pathology - ajp.amjpathol.orgresponse in the labeled cells surrounding the lesion, whose
numbers remained static between normal and lesioned
tissue. Gfp-labeled processes were not seen to extend into
the area of demyelination, suggesting that closely adjacent
oligodendrocytes do not extend new myelin sheaths to
adjacent demyelinated axons. However, it remains possible
that this occurs at a low level that we were not able to
visualize, in part because of the difﬁculties of accurately
deﬁning the lesion border, or that the demyelination model
used in our study is not conducive to such an event.
Regardless, efﬁcient remyelination was achieved without a
signiﬁcant contribution from mature oligodendrocytes.
In conclusion, mature oligodendrocytes do not appear to
contribute to remyelination to any detectable extent. OPs
present throughout the adult central nervous system are the
source of remyelinating oligodendrocytes, and strategies to
enhance endogenous remyelination in the context of clinical
disease and aging should focus on enhancement of the OP
function, as opposed to promotion of oligodendrocyte
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